Search Browse Earnings

NextCure, Inc.

Nasdaq:NXTC

Pharmaceutical Preparations·BELTSVILLE, MD

Overview All Filings Sum Fin Credit Insiders Governance

Overview All Filings Sum Fin Credit Insiders Governance

Summary Financials

NextCure, Inc. — SlamSEC

Revenue

$22.4M

+252.6% YoY

FY 2021

Adj. EBITDA

-$56.8M

-254.0% margin

FY 2025

Net Income

-$55.7M

-248.7% margin

FY 2025

EPS (Diluted)

-$23.88

FY 2025

Stock Price

$12.39

-3.8%

2026-03-06

52W Range

$2.69 – $15.74

P/E Ratio

-0.5x

Market Cap

$44.1M

Cash

$27.7M

FY 2025

Total Debt

$1.8M

FY 2021

Net Cash

$25.9M

FY 2021

Enterprise Value

$18.2M

Debt / EBITDA

0.5x

FY 2021

EV / EBITDA

-0.3x

Employees

—